WuXi Biologics subsidiary WuXi Vaccines has agreed to sell its vaccine manufacturing facility in Dundalk, Ireland, to MSD for approximately $500m. Expected to close in the first half of 2025, the deal ...

WuXi Biologics is expected to deliver faster sales growth and higher margins this year. Click here to find out why I upgraded ...

WuXi 2269-1.25%decrease; red down pointing triangle Biologics agreed to sell an overseas vaccine facility to Merck MRK-1.32%decrease; red down pointing triangle & Co. for half a billion dollars ...

Wuxi Biologics (Cayman) ( (HK:2269) ) has provided an announcement.

CMB International Securities analyst Jill Wu has maintained their bullish stance on WXIBF stock, giving a Buy rating on January 13.Stay Ahead ...

WuXi Biologics (stock code: 2269.HK) is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover ...

SHANGHAI, Jan. 2, 2025 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced that it has ...

WuXi Biologics' CEO Chris Chen has denied that the company’s sale of its less than four-year-old Ireland site is due to the threat of the US Biosecure Act, and said that the number of new ...

China's WuXi Biologics said on Monday it will sell its vaccine facility in Ireland to U.S. drugmaker Merck & Co for about $500 million. The Financial Times had reported in October that WuXi and WuXi ...